Literature DB >> 21236446

Brain abnormalities in neuromyelitis optica.

Jee-Eun Kim1, Sung-Min Kim, Suk-Won Ahn, Bung Chan Lim, Jong Hee Chae, Yoon-Ho Hong, Kyung-Seok Park, Jung-Joon Sung, Kwang-Woo Lee.   

Abstract

BACKGROUND: Differentiating neuromyelitis optica (NMO) from multiple sclerosis (MS) is a real challenge in the clinical field. In the past, NMO (not MS), was inferred when abnormality was not detected in the brain magnetic resonance imaging (MRI). Recently, some studies have reported abnormalities in the brain MRIs of NMO, but only few among the Asian population. The aim of this study was to evaluate the frequency of brain MRI among Korean NMO patients and characterize findings that might be helpful to distinguish NMO from MS.
METHODS: Medical records, NMO-IgG, and brain MRI of 17 patients diagnosed with NMO by the revised diagnostic criteria of Wingerchuk et al. (2006) [6] from 2008 to 2010, were reviewed.
RESULTS: 11 out of 17 patients (64.7%) had abnormal MRI findings. More than two lesions were detected in most patients. The majority of patients with brain MRI abnormality showed nonspecific (5 patients) or atypical (6 patients) findings. Cerebral white matter was most frequently involved (58.8%). 3 patients (17.6%) involved corpus callosum, 4 (23.5%) with internal capsule, 2 (11.8%) with cerebellum, and 3 (17.6%) with brainstem. There were 5 (29.4%) patients who met the Paty et al. criteria (1988) [15] and 3 patients (35.3%) who met the multiple sclerosis (MS) spatial distribution diagnostic criteria of Barkhof et al. (1997) [14] in their brain MRI.
CONCLUSIONS: Brain abnormalities have been frequently found among Korean NMO patients and the frequencies have been reported to be higher than that of Caucasians. Current MS spatial distribution criteria, such as Paty et al. (1988) [15] or Barkhof et al. (1997) [14], are not sufficient to discriminate NMO from MS in brain MRI findings. Our results will provide valuable information that would be useful in establishing future revising criteria for NMO.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21236446     DOI: 10.1016/j.jns.2010.12.001

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  25 in total

1.  Natalizumab and the development of extensive brain lesions in neuromyelitis optica.

Authors:  Maciej Juryńczyk; Krzysztof Zaleski; Krzysztof Selmaj
Journal:  J Neurol       Date:  2013-05-30       Impact factor: 4.849

2.  White matter disease: Early treatment of inflammatory demyelinating disease.

Authors:  Naraporn Prayoonwiwat; Sasitorn Siritho
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

3.  Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions.

Authors:  Yanqiang Wang; Lei Zhang; Bingjun Zhang; Yongqiang Dai; Zhuang Kang; Ciyong Lu; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  J Neurol       Date:  2014-03-09       Impact factor: 4.849

4.  Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis.

Authors:  E Bulut; J Karakaya; S Salama; M Levy; T A G M Huisman; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

Review 5.  Cognitive dysfunction in adult patients with neuromyelitis optica: a systematic review and meta-analysis.

Authors:  Hao Meng; Jun Xu; Chenling Pan; Jiaxing Cheng; Yue Hu; Yin Hong; Yuehai Shen; Hua Dai
Journal:  J Neurol       Date:  2016-12-01       Impact factor: 4.849

6.  The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation.

Authors:  S Jarius; B Wildemann
Journal:  J Neurol       Date:  2012-01-12       Impact factor: 4.849

7.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

Review 8.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

9.  Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.

Authors:  Lucy Matthews; Rita Marasco; Mark Jenkinson; Wilhelm Küker; Sebastian Luppe; Maria Isabel Leite; Antonio Giorgio; Nicola De Stefano; Neil Robertson; Heidi Johansen-Berg; Nikos Evangelou; Jacqueline Palace
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

10.  Cognitive functions in Egyptian neuromyelitis optica spectrum disorder.

Authors:  Sara Salama; Hazem Marouf; M Ihab Reda; Amal R Mansour; Osama ELKholy; Michael Levy
Journal:  Clin Neurol Neurosurg       Date:  2019-11-25       Impact factor: 1.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.